Objective-RAISE-ETP compared NAVIGATE, a comprehensive program for first-episode psychosis, to clinician-choice treatment over two years. Quality of life and psychosis and depressive symptom outcomes were better with NAVIGATE. Compared with prior comprehensive first-episode psychosis interventions, NAVIGATE medication prescription included unique elements of 1) detailed first-episode psychotropic medication guidelines and 2) a computerized decision support system to facilitate shared decision making regarding prescriptions. We present comparisons between the treatment conditions of the psychotropic medications prescribed, side effect experienced, metabolic outcomes and scores from the Adherence Estimator that assesses beliefs related to intentional non-adherence.
Introduction
Comprehensive specialty care treatment for early psychosis has been strongly advocated (e.g. (1)) and several randomized comparisons performed (2) (3) (4) (5) (6) (7) (8) . Given the critical role of medication treatment, it is notable that comprehensive specialty care interventions varied widely in how much medication treatment was specified and that such limited information was provided on treatment goals and guidelines, prescriber training and treatment delivery. In published manuscripts, medication prescription was not mentioned for the GET UPthe LEO study (2) intervention employed "low dose atypical antipsychotic regimens" while COAST (6) used "optimum atypical medication", and OPUS (4) used medication treatment "designed individually according to national guidelines". In contrast, medication prescription in the NAVIGATE intervention of the Recovery After an Initial Schizophrenia Episode -Early Treatment Program (RAISE-ETP) included unique elements of 1) programdeveloped first-episode medication guidelines, 2) a computerized decision support system to support shared decision making regarding prescriptions and 3) training and ongoing support for prescribers throughout the study.
We examined NAVIGATE's effects on prescription practices and measures of general side effects, vital signs and cardiometabolic outcomes using data from the RAISE-ETP study (5, 9) comparing NAVIGATE treatment with clinician-choice Community Care. These analyses complement findings (5) of better symptom Positive and Negative Syndrome Scale (10) and Calgary Depression Scale for Schizophrenia (11) outcomes with NAVIGATE compared with Community Care.
Methods
NAVIGATE treatment (12) included coordinated medication management, psychoeducation, resilience-focused individual therapy and supported employment and education. NAVIGATE team members supported each other's efforts including adherence to NAVIGATE medication guidelines. Individual resilience-focused therapy included modules about medications and health-promoting behaviors.
Medication procedures
Research data and treatment guidelines (13) (14) (15) (16) (17) support distinctive medication strategies for first-episode and multi-episode patients. Our approach to assisting busy clinicians at our non-academic "real world" sites to incorporate specialized first-episode treatment strategies into their work started by developing first-episode medication guidelines based upon review of the treatment literature. Medication recommendations were limited to marketed agents given the community facilities setting. NAVIGATE treatment used a shared decision making model (18) . For medication selection, patients and prescribers chose among medications with equivalent evidence based upon patient factors and preferences. The shared decision making framework plus the failure of any antipsychotic to demonstrate superior efficacy for initial treatment of psychosis led to the decision to group recommended medications into treatment stages instead of a single medication algorithm. Medication grouping criteria included data from first-episode or adolescent patients with psychotic disorders and low side effect risk. Symptom remission rather than symptom improvement was the treatment goal. If satisfactory initial response was not obtained, medications were chosen from subsequent stage groups. The antipsychotics available in the United States during guideline development with data from contemporary studies with first-episode or adolescent populations were aripiprazole, chlorpromazine, clozapine, haloperidol, olanzapine, quetiapine, risperidone and ziprasidone. Because of concerns about side effects for chlorpromazine, clozapine, haloperidol and olanzapine and for less maintenance treatment efficacy for haloperidol (19, 20) , these medications were excluded from the stage 1 group (consisting of the remaining studied agents aripiprazole, quetiapine, risperidone and ziprasidone). Stage 2 agents were the stage 1 agents plus chlorpromazine, haloperidol and olanzapine; clozapine was a stage 3 agent. For each medication, first-episode dosing guidelines were developed (e.g. for risperidone, starting dose of 1-2 mg/day, target dose of 3-4 mg/day and maximum dose of 8 mg/day). Over the two-year RAISE-ETP treatment duration, continuous antipsychotic treatment was recommended. Patients and prescribers evaluated the potential benefits and disadvantages of switching antipsychotics for participants who entered RAISE-ETP with prescriptions not conforming to NAVIGATE stage 1 principles. Participants who agreed to take antipsychotics but not a NAVIGATE-preferred medication were prescribed their preferred agent; participants who declined to take any antipsychotic had ongoing prescriber monitoring visits. Side effect management strategies (dose reduction being the usual initial strategy) and for monitoring and treatment of cardiometabolic abnormalities were also provided. Since the depressive symptoms of first-episode patients often remit with antipsychotic treatment alone (21), prescription of adjunctive antidepressants for all firstepisode patients with depressive symptoms was not advised. Instead, consideration of the persistence and severity of depression was suggested when making decisions about adjunctive antidepressants. The detailed NAVIGATE medication manual is available at (22).
Participants and prescribers used COMPASS, a NAVIGATE-developed computer clinical decision making tool accessed via a secure web-based platform. COMPASS was designed to facilitate patient-prescriber communication. Participants entered information about symptoms, side effects, treatment preferences, medication adherence and attitudes, and substance use into COMPASS before meeting with prescribers. Vital signs data and laboratory test results were also entered. Using a measurement-based approach, the prescriber's assessments, also entered directly into COMPASS, were modified/informed based upon these prior entered data. Integrating participant treatment priorities and the prescriber's assessments, COMPASS provided suggested guideline treatments. Prescribers and participants then made medication decisions informed by these recommendations. NAVIGATE guidelines recommended a prescriber visit at least monthly for the first two years of treatment.
NAVIGATE prescriber training included an in-person group two-day session on NAVIGATE principles followed by individual training via teleconferencing on technical aspects of COMPASS. Monthly group prescriber teleconferences with the NAVIGATE Central Team included group feedback about clinical challenges and NAVIGATE treatment options for these and review of relevant psychosis literature.
RAISE-ETP study
This report focuses on the first two years of patient participation, the minimum by design for all participants. Patients aged 15 to 40 years receiving treatment for a first-episode of psychosis due to schizophrenia, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, or psychotic disorder not otherwise specified and who had taken ≤6 months of antipsychotics during their lifetime were recruited from 34 community mental health treatment facilities nationwide without preexisting first-episode specialty care programs. Written informed consent was obtained from adult participants; written consent from guardians and written assent from participants younger than 18. RAISE-ETP was conducted under the guidance of the NIMH Data and Safety Monitoring Board and of Institutional Review Boards at the coordinating center and the sites. RAISE-ETP employed cluster randomization. The 17 randomly-assigned NAVIGATE sites recruited 223 participants and the 17 Community Care sites 181 participants. Community Care clinicians were trained on recruitment, informed consent and study assessment procedures but received no guidance about treatment approaches. The study design and assessments have been previously described (9) . Monthly, patient self-report data on prescription (medication and dose) and on number of medication management visits were obtained with the Service Use and Resource Form (23) . At baseline, 3, 6, 12, 18 and 24 months, participants reported in a yes/no format whether they had experienced during the past 30 days 21 common side effects of antipsychotic medications (dizziness, blurred vision, excess saliva, nausea, constipation, increased appetite, weight gain, weight loss, restlessness, shaking, rigidity, fatigue, drowsiness, excess sleep, insomnia, decreased libido, other sexual problems, breast swelling or discharge, impaired sexual performance and amenorrhea). Concurrently, vital signs were obtained and fasting blood samples collected. Participants taking medications also completed the Adherence Estimator, a self-report scale (24) measuring beliefs related to intentional non-adherence that has been validated against pharmacy claims (25) .
Statistical analyses
As RAISE-ETP participants had psychotic disorders, our paramount medication question was whether NAVIGATE compared with Community Care treatment was associated with greater likelihood of antipsychotic prescription. We also compared the likelihood of participants receiving a prescription that conformed to NAVIGATE stage 1 ("first-line"). By study month, we determined if participants were prescribed antipsychotic mono-therapy with a NAVIGATE stage 1 antipsychotic. We allowed a broad range of antipsychotic doses (instead of our targeted dose ranges) to qualify as first-line to allow for low doses for antipsychotic initiation and higher doses for management of treatment-resistance (e.g. the qualifying dose range for risperidone was 1-8 mg per day, based upon 1mg/day being the NAVIGATE recommended lowest starting dose and 8 mg/day the highest dose). Participants receiving concurrent stimulants were classified as not being prescribed first-line medications; participants prescribed antipsychotic mono-therapy with paliperidone at approved doses were classified as being prescribed a first-line medication (NAVIGATE training included review of the administration advantages of paliperidone palmitate over risperidone microspheres). Given that depression outcomes were better with NAVIGATE than Community Care, we also compared the likelihood of antidepressant prescription between conditions. Other medication explorations: Antipsychotic prescription involves choice of agent and dose. To characterize these, we examined the likelihood of the most commonly prescribed agents being prescribed (irrespective of dose or other medications prescribed) and the mean modal dose for oral formulations of each agent.
General side effects
The primary measure was the total number of side effects (excluding amenorrhea being not applicable to male participants). Secondary measures were amenorrhea and a priori side effect groupings (sedation, extrapyramidal symptoms, anticholinergic side effects, increased appetite or weight gain and sexual problems). A side effect group was considered present if any side effect within that group was present.
Longitudinal analyses of the any-antipsychotic-use (yes/no) outcome and other binary outcomes reported in Table 1 and Supplemental Table 2 were performed using a generalized linear mixed models analysis with a logit link. PROC GLIMMIX in SAS 9.4 was used. Each subject's modal dose was calculated and the mean modal dose was compared between conditions using a mixed models analysis with a random intercept for site. Longitudinal analysis of the cardiometabolic outcomes (Table 3 ) and total number of side effects (Table 4) was performed with mixed models using the PROC MIXED procedure in SAS 9.4. The mixed models approach takes into account the within subject correlation of the repeated measurements. The difference in the trajectories between the two treatment groups was assessed by including a time-by-treatment interaction term in the mixed models. Least square means which estimate the population marginal means for a balanced design are reported in Table 3 and 4. In all longitudinal analysis, cluster correlation within site was addressed by including a random intercept for subjects nested within sites. The limited number of clusters in clustered randomized trials can cause an imbalance between treatment groups on baseline measures, potentially confounding the relationship between treatments and outcomes. As per the overall RAISE-ETP statistical analysis plan (5, 26) , variables with significant baseline group imbalance were included as covariates in our analyses if they were correlated with the outcome of interest at a level of ≥.30.
Multiple comparisons adjustments were done by controlling the False Discovery Rate (FDR) using the Benjamini-Hochberg's procedure (27, 28) . The R 'multtest' package was used. FDR correction was applied to groups of analyses that addressed the same clinical question. The blocks were: medication classes (Table 1) ; specific agents (Table 1) ; daily dose (Table  2) ; vital signs (Table 3) ; laboratory findings (Table 3) ; number of side effects (Table 4) and specific side effects (Supplemental Table 2 ). Significance was declared for analyses with FDR-corrected p-values <0.05.
Odds ratios in Table 1 were converted to Cohen's d using the formula . Elsewhere, effect sizes of the difference between least square means were calculated using the formula:
, where t = t-value and df = degrees of freedom.
Results

Participants
Supplemental Table 1 presents participant characteristics. Briefly, 73% were men, the most frequent racial backgrounds were Caucasian (54%) and African-American (37%), the mean age was 23 years and the most frequent diagnoses were schizophrenia (53%) and schizophreniform disorder (14%).
COMPASS implementation
Two hundred eleven of the 223 NAVIGATE participants (94.6%) completed one or more COMPASS visits. During their first 2 years of study participation, NAVIGATE participants completed 3004 COMPASS assessments.
Number of medication visits
As presented in Figure 1 , NAVIGATE compared with Community Care participants had significantly more medication visits (treatment-by-time interaction F=3.78, df=23, 9246, p<0.0001; effect of treatment, F=12.80, df=1, 9246, p=0.0003). Over the 2 years, the least square means estimate of the number of medication visits per month was 0.292 (95% CI: 0.226, 0.357) for Community Care and 0.554 (95% CI: 0.423, 0.685) for NAVIGATE.
Medication prescription
As shown in Table 1 As shown in Tables 1 and 2 , the specific antipsychotics prescribed and mean modal dose did not significantly differ between conditions for any of the major antipsychotics. At a trend level, NAVIGATE compared with Community Care participants were more likely to be prescribed aripiprazole and less likely to be prescribed haloperidol.
Vital Sign and Cardiometabolic Outcomes
As presented in Table 3 , both weight and BMI analyses revealed significant treatment-bytime interactions. The estimated mean increase in BMI from baseline to month 24 was 2.10 (95% CI: 
General Side Effects
Analysis of the number of side effects revealed a significant treatment-by-time interaction.
As shown in Table 4 , NAVIGATE and Community Care participants reported equal number of side effects at baseline but NAVIGATE participants reported fewer side effects at 
Discussion
The NAVIGATE model was developed to treat a specialized population, patients with firstepisode schizophrenia and related disorders, in non-academic "real world" settings. An initial question was whether the COMPASS decision support system could be implemented and used in community settings. The 3,004 completed COMPASS visits provide an affirmative response to this question. Further, NAVIGATE participants had on average slightly less than twice as many monthly medication management visits (0.554 versus 0.292) as Community Care participants and the pattern of more NAVIGATE medication visits was present across all trial phases. These findings support the sustained feasibility and acceptability of the NAVIGATE treatment model in comparison with usual care. NAVIGATE prescribers had the support of a manual, training by the Central Team in treatment principles and COMPASS use, the guidance that was built into the COMPASS visits and access to monthly teleconferences.
The next key question was whether NAVIGATE recommendations and the COMPASS system influenced prescriptions? Regarding antipsychotics, prescriptions for any antipsychotic as well as prescriptions conforming to NAVIGATE first-line antipsychotic principles were significantly more likely with NAVIGATE compared with Community Care. Prescriptions for specific antipsychotics did not differ significantly. At a trend level, aripiprazole prescriptions were more likely and haloperidol prescriptions less likely for NAVIGATE participants, consistent with NAVIGATE-preferred medication stages. Clozapine was required only infrequently with our first-episode population. Rates were greater with NAVIGATE than Community Care (4.7% versus 1.8% of months with prescription data) but the difference was not significant. Given the NAVIGATE emphasis upon low dose strategies, we anticipated that NAVIGATE prescriptions would be for lower doses. Instead we found no differences, probably resulting from the finding that the mean modal doses for Community Care antipsychotic prescriptions overall were within recommended first-episode treatment ranges.
In a prior analysis of medication prescription at RAISE-ETP entry (29) , 39.2% of participants were receiving problematic prescriptions. An important question is whether rates of problematic medication prescriptions change during extended treatment. Differences in data sources available at baseline and longitudinally precluded applying the prior baseline criteria to the current longitudinal analyses. Prescriptions that do not conform with NAVIGATE first-line principles may be clinically appropriate (e.g. for symptoms that do not improve with a first-line medication). Nevertheless, the extent that patients with baseline prescriptions not conforming to NAVIGATE first-line principles later receive a first-line prescription does provide one metric to evaluate whether prescription patterns improve over time. It is encouraging that substantial numbers of Community Care participants receiving prescriptions not conforming with NAVIGATE first-line principles eventually received a NAVIGATE first-line prescription and that NAVIGATE compared with Community Care treatment significantly increased the likelihood of this change.
We earlier reported that NAVIGATE participants had lower depressive symptoms (5) . The present analysis shows that this was achieved with significantly less likelihood of antidepressant prescription. This may reflect the finding that the depressive symptoms of patients with first-episode psychosis often remit with antipsychotic treatment alone (21) and this information was included in NAVIGATE training. Further, the NAVIGATE psychosocial interventions (12) may have contributed to better depression symptom outcomes. A recent meta-analysis (30) found small beneficial effects for adjunctive antidepressants for depression and negative symptoms with people with schizophrenia. First-episode subgroup analyses did not detect effects but the number of first-episode studies included was small. Negative symptom outcomes in RAISE-ETP did not differ between conditions despite less antidepressant use. Further research is needed to determine 1) whether first-episode psychosis specialty care treatment consistently produces better depression outcomes with less antidepressant prescription and 2) antidepressant effects (if any) on negative symptoms among first-episode patients.
The lower number of side effects among NAVIGATE participants is notable given that NAVIGATE participants were more likely to be prescribed antipsychotics and the side effects assessed were ones specifically associated with antipsychotic treatment. NAVIGATE training emphasized side effect prevention and/or minimization and the COMPASS system included structured side effect assessments at each visit and decision support for side effect management. These may have contributed to less side effect burden from prevention efforts and better detection and treatment of antipsychotic-induced side effects when they occurred. The less frequent use of antidepressants at NAVIGATE sites may also have contributed to fewer side effects.
Although significant differences between NAVIGATE and Community Care outcomes were found for weight gain/BMI, the differences were small in magnitude. Nevertheless, given the likely future duration of antipsychotic exposure, such differences are potentially important. Given the potential adverse effects of antipsychotics on lipid and glucose metabolism, it is reassuring that NAVIGATE treatment enhanced antipsychotic prescription compared with Community Care while producing similar laboratory outcomes. Nevertheless, the mean 6.5 kg weight gain among NAVIGATE participants shows that additional tools for preventing adverse metabolic outcomes are needed.
Medication data from other comparisons of comprehensive first-episode specialty care with usual care are limited. Broadly, data from our and other trials (31, 32) and from demonstration projects (33) suggest that comprehensive care treatment may be associated with better medication treatment. Intervention compared with control condition participants in the LEO trial were significantly less likely to stop prescribed medication (31) and in the OPUS trial more likely at a trend level of significance to be taking an antipsychotic at 1-year but not at 2-year follow-up (32) .
A limitation of RAISE-ETP medication data is the reliance on patient self-report. Self-report was necessary as a source instead of clinic or pharmacy records to permit medication tracking for participants who discontinued treatment at their RAISE-ETP site. Patient selfreport may have introduced inaccuracies in the overall data, but should have had limited impact on the NAVIGATE versus Community Care comparisons, as participants in both conditions should have had equivalent ability to report treatments prescribed. It should be noted that our data are for medications prescribed instead of medications taken. The Adherence Estimator data documented an advantage with NAVIGATE but not Community Care treatment for medication beliefs related to adherence. An important future research question is whether these belief changes translate into improved adherence.
In summary, we previously reported differential improvement with the comprehensive NAVIGATE treatment model compared to Community Care in quality of life and clinical psychopathology outcomes (5) . We now add findings of greater frequency of antipsychotic prescription, reduced side effect burden, reduced antidepressant prescription, and some reduction of the consequences of antipsychotics on medical health. The NAVIGATE model of measurement-based care in the context of shared decision making provides a framework for incorporating future advances. As knowledge of first-episode medication treatment advances, future medication guideline improvements may produce even better outcomes than our current efforts.
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